Your browser doesn't support javascript.
Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center.
Meyerhardt, Jeffrey A; Yue, Hong; Nowak, Radoslaw P; Brais, Lauren; Ma, Chao; Johnson, Samantha; Harrod, Joanna; Burman, Shourya S Roy; Hendrickson, Lynn M; Fischinger, Stephanie; Alter, Galit; Hahn, William; Johnson, Bruce E; Fischer, Eric S.
  • Meyerhardt JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Yue H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Nowak RP; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States of America.
  • Brais L; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Ma C; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States of America.
  • Johnson S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Harrod J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Burman SSR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Hendrickson LM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Fischinger S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Alter G; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States of America.
  • Hahn W; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America.
  • Johnson BE; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States of America.
  • Fischer ES; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, United States of America.
PLoS One ; 17(4): e0266791, 2022.
Article in English | MEDLINE | ID: covidwho-1785206
ABSTRACT

BACKGROUND:

The COVID-19 pandemic led to emergency measures to continue patient care and research at a comprehensive cancer center while protecting both employees and patients. Determining exposure and infection rates with SARS-CoV-2 were important to adjust workplace policies over time.

METHODS:

Dana-Farber Cancer Institute (DFCI) has over 7,000 employees. Participation was voluntary. After consent, participants completed questionnaire of demographics, exposures and risk factors for COVID-19 illness at each time point (baseline, 3, 6, and 12 months) along with blood draws for SARS-CoV-2 antibody testing. Primary measure was determination of titers of SARS-CoV-2 spike protein IgG over time.

RESULTS:

In total, 745 employees enrolled from May 2020 to February 2021 (mean [SD] age, 40[14] years; 572[80%] women). From May to July 2020, 47 of 519 employees (9.2%, 95% confidence interval [CI] 6.7-12.0%) tested positive for SARS-CoV-2 spike protein IgG antibodies. Three months later, 40 of 428 employees had positive antibodies (8.5%, 95% CI 6.0-11.0%) with 17 newly positive. At month 6, 78.5% of participants reported having received at least one dose of vaccine and the positivity rate for those vaccinated was 98% (95% CI, 95-100%). Spike protein IgG titers for those vaccinated were 7.9 times higher than participants not vaccinated (median IgG titer = 0.28 for positive antibody but not vaccinated versus 2.2 for vaccinated) but demonstrate evidence of waning over time.

CONCLUSIONS:

SARS-CoV-2 antibody positivity remained less than 10% at a single comprehensive cancer center prior to vaccination and there is evidence of waning IgG titers over time after vaccination.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Female / Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0266791

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Neoplasms Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adolescent / Female / Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0266791